227609-15-6

Basic information

• Product Name: Thieno[3,2-b]quinolin-8(4H)-one, 9-(3,4-difluorophenyl)-2,3,5,6,7,9-hexahydro-, 1,1-dioxide
• CAS NO: 227609-15-6
• Molecular Formula: C17H15F2NO3S
• Molecular Weight: 351.374
• Mol File: 227609-15-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Thieno[3,2-b]quinolin-8(4H)-one, 9-(3,4-difluorophenyl)-2,3,5,6,7,9-hexahydro-, 1,1-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: Thieno[3,2-b]quinolin-8(4H)-one, 9-(3,4-difluorophenyl)-2,3,5,6,7,9-hexahydro-, 1,1-dioxide(227609-15-6)
• EPA Substance Registry System: Thieno[3,2-b]quinolin-8(4H)-one, 9-(3,4-difluorophenyl)-2,3,5,6,7,9-hexahydro-, 1,1-dioxide(227609-15-6)

Safety Data

• Hazardous Substances Data: 227609-15-6(Hazardous Substances Data)

Upstream product

• 17115-51-4 3-oxotetrahydrothiophene dioxide 
• 34036-07-2 3,4 difluorobenzaldehyde 
• 5220-49-5 3-amino-cyclohex-2-enone 

Relevant articles and documents

Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinoline-8(4H)-one 1,1-dioxide K ATP channel openers: Discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent KATP opener that selectively inhibits spontaneous bladder contractions

Structure-activity relationships were investigated on a novel series of sulfonyldihydropyridine-containing KATP openers. Ring sizes, absolute stereochemistry, and aromatic substitution were evaluated for K ATP activity in guinea pig bladder cells using a fluorescence-based membrane potential assay and in a pig bladder strip assay. The inhibition of spontaneous bladder contractions in vitro was also examined for a select group of compounds. All compounds studied showed greater potency to inhibit spontaneous bladder contractions relative to their potencies to inhibit contractions elicited by electrical stimulation. In an anesthetized pig model of myogenic bladder overactivity, compound 14 and (-)-cromakalim 1 were found to inhibit spontaneous bladder contractions in vivo at plasma concentrations lower than those that affected hemodynamic parameters. Compound 14 showed approximately 5-fold greater selectivity than 1 in vivo and supports the concept that bladder-selective KATP channel openers may have utility in the treatment of overactive bladder.

Potassium channel openers

Compounds having the formula are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.